Akari Therapeutics (AKTX) announced Thursday morning that it plans to advance Coversin towards Phase III clinical studies in the first quarter of 2018. The decision was made following a recent Type B End of Phase II Meeting with the FDA.
from RTT - Before the Bell http://ift.tt/2xz42YP
via IFTTT
No comments:
Post a Comment